Acurx says FDA conditionally accepts CIFBEZY brand name for ibezapolstat
ACXP•Trademark application allowed by USPTO
The company said the USPTO allowed the CIFBEZY trademark application, supporting future commercialization plans tied to a potential NDA.
FDA conditionally accepts proposed brand name
Acurx said the FDA has conditionally accepted CIFBEZY as the proposed brand name for its lead antibiotic candidate, ibezapolstat.
